In the CNO-first group, 1 patient out of 27 (4%) was treated with etanercept, and the remaining received a TNFα inhibitor (TNFα-i) only after the diagnosis of IBD, while in the IBD-first group, 5 patients out of 11 (45%) were under TNFα-i treatment when bone symptoms appeared (p-value = 0.004; [95% CI 1.7–1054.4]). This evidence concerns the gene TNF and inflammatory bowel disease.